Financial report for the period 1 January 2024 to 30 September 2024 ... Read more
Illumina, Inc. shared its financial results for the third quarter of fiscal year 2024, demonstrating resilience amidst macroeconomic challenges and reflecting solid operational performance. CEO Statement from Jacob Thaysen: "During the third... Read more
Reports record third quarter 2024 revenue of $7.6 million, representing growth of 24%compared to the third quarter of 2023 Placed seven Growth Direct® systems in the third quarter of 2024, marking the highest number of system placements sinc... Read more
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, reported its consolidated financial results for the third quarter ended September 30, 2024 and reviewed recent business highlights. “Alnylam co... Read more
Financial report for the period 1 January 2024 to 30 September 2024 ... Read more
Syndax Pharmaceuticals (Nasdaq: SNDX) and Royalty Pharma plc (Nasdaq: RPRX) announced that Syndax has entered into a $350 million synthetic royalty funding agreement with Royalty Pharma based on U.S. net sales of Niktimvo™ (... Read more
Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlands and Sweden, announced a substantial expansion of its Bioanalytical Services in the Net... Read more
Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, issued the following open letter to customers: To Catalent’s Valued Customers, I want to correct a few key inaccuracie... Read more
© 2024 Biopharma Boardroom. All Rights Reserved.
